title: Magnetic resonance imaging to measure therapeutic response using an orthotopic model of human pancreatic cancer.
abstract: Pancreatic cancer is one of the most incurable and lethal human cancers in the United States. To facilitate development of novel therapeutic agents, we previously established an orthotopic pancreatic tumor model that closely mimics the natural biological behavior of human pancreatic cancer. In this study, magnetic resonance imaging (MRI) techniques were developed to detect tumor formation noninvasively and monitor serially tumor growth kinetics in this orthotopic model used for experimental drug testing. By using an optimized T2-weighted imaging method, we were able to distinguish human pancreas cancer from normal mouse pancreas. Orthotopic tumor formation was detected as early as day 1 after tumor cell implantation with a tumor volume as small as 12 mm3. Mice with evidence of tumor were separated into four treatment groups: control, auristatin-PE, gemcitabine, and their combination. After treatment, the mice were imaged at least three times before termination of the experiment. Comparison between MRI tumor volume measurements and tumor weights made at biopsy resulted in a correlation coefficient of 0.98. The tumor growth curves constructed from serial magnetic resonance imaging (MRI) measurements clearly showed tumor growth inhibition in treated mice compared with the control group. As expected, the group treated with the combination had the highest response rate compared with either auristatin-PE or gemcitabine alone, and the data were statistically highly significant (p < 0.004). From these results, we conclude that noninvasive MRI can be used to monitor serially therapeutic response in this orthotopic human pancreatic tumor model and can be used in the future to evaluate novel antitumor agents before human studies.
authors.affiliation: Cancer Biology Program, Karmanos Cancer Institute, Wayne State University, Detroit, Michigan, USA.
authors.forename: Z
authors.initials: Z
authors.lastname: He
authors.forename: J L
authors.initials: JL
authors.lastname: Evelhoch
authors.forename: R M
authors.initials: RM
authors.lastname: Mohammad
authors.forename: N V
authors.initials: NV
authors.lastname: Adsay
authors.forename: G R
authors.initials: GR
authors.lastname: Pettit
authors.forename: V K
authors.initials: VK
authors.lastname: Vaitkevicius
authors.forename: F H
authors.initials: FH
authors.lastname: Sarkar
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy* / Q000473:pathology; D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008279:Magnetic Resonance Imaging / Q000379:methods; D051379:Mice; D016513:Mice, SCID; D009842:Oligopeptides / Q000627:therapeutic use*; D010179:Pancreas / Q000473:pathology; D010190:Pancreatic Neoplasms / Q000188:drug therapy* / Q000473:pathology; D014407:Tumor Cells, Cultured; D023041:Xenograft Model Antitumor Assays
chemical_list: D000970:Antineoplastic Agents; D009842:Oligopeptides; C105791:soblidotin